Link here. Highlights · Clinical study interim results demonstrate ReCell® superiority as treatment for hypopigmentation. · Statistically significant pigment restored in patients’ hypopigmented scars treated with ReCell. · Results support the Company’s commercial strategy for use of ReCell in aesthetic plastic surgery. · Study results delivered at key European conferences, enhancing ReCell industry profile. Northridge, Calif., […]

Australia, 8 April 2014 – Link here. NORTHRIDGE, Calif., and CAMBRIDGE, United Kingdom, 8 April 2014 – Regenerative medicine company Avita Medical Limited “Avita Medical” (ASX:AVH), (OTCQX:AVMXY) is pleased to advise that it has developed and released to market a new version of ReCell® ‘Spray‐on Skin®’ that no longer requires refrigeration. This greatly improves the commercial and […]

ASX announcement link here. Avita CFO Mr Tim Rooney appointed interim CEO following resignation of Managing Director and CEO William Dolphin. Ian MacPherson elected as interim board Chairman following resignation of Dalton Gooding as Chairman. Internal progress made to review company remuneration report.

..Two largest shareholders to vote against remuneration report 20 November 2013: Leading Australian life sciences investment group BioScience Managers today confirmed it will vote against the remuneration report of spray-on skin company Avita Medical Limited (ASX:AVH) at the company’s AGM on Friday 22 November. With the company’s largest shareholder Australian Ethical also set to vote against […]

Link here. Date of Meeting: 22 November 2013 Time of Meeting: 2pm WST Place of meeting: Function Room, QV1, 250 St Georges Terrace, Perth, WA 6000